Core Insights - Recursion has appointed Dr. Vicki Goodman as the new Chief Medical Officer, effective April 6, 2026, succeeding Dr. David Mauro [1][6] - Dr. Goodman brings over two decades of experience in oncology drug development and has held senior leadership roles in both biotech and large pharmaceutical companies [2][4][5] - The company is focused on advancing its clinical pipeline and achieving key clinical and regulatory milestones, leveraging Dr. Goodman's expertise to enhance its development programs [2][3] Company Overview - Recursion is a clinical-stage TechBio company that aims to decode biology to significantly improve lives, with a focus on developing investigational medicines across various therapeutic areas including oncology, rare diseases, neuroscience, and immunology [8] - The company utilizes an AI-native, end-to-end drug discovery and development platform known as Recursion OS, which integrates biology, chemistry, and clinical development into a unified intelligence system [8] - Recursion's infrastructure includes automated biology and chemistry laboratories in Salt Lake City, Utah, and Milton Park, Oxfordshire, designed to generate proprietary data at an industrial scale [9] Leadership Transition - Dr. David Mauro, the outgoing CMO, has contributed significantly to strengthening Recursion's medical organization and advancing its clinical portfolio over the past three years [6][7] - The leadership transition is seen as a strategic move to enhance the company's capabilities in navigating critical regulatory and clinical development stages [3][7]

Recursion Pharmaceuticals Conference Call Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Event**: 2026 Conference held on March 09, 2026 Key Points Strategic Focus - Recursion is concentrating on three strategic areas: 1. Doubling down on proof points 2. Surgical investments in the platform 3. Pairing ambition with discipline [6][8] - The company is making rapid go-no-go decisions across its pipeline, emphasizing data-driven decision-making [6][7]. Pipeline and Portfolio Management - Recursion is synthesizing approximately 90% fewer compounds to reach advanced candidates compared to industry standards, achieving this in about half the time [7]. - The company has seven internal programs advancing and is committed to transparency in its decision-making process [9][10]. - For 2026, Recursion expects a gross burn of less than $390 million, excluding inflows from partnerships [12][13]. Partnership Dynamics - Recursion has crossed over half a billion in upfront and milestone payments from partnerships, including significant contributions from Roche and Sanofi [18][21]. - The company has a potential of $343 million in milestones per Sanofi program, with $193 million being pre-commercial [24]. - Recursion's partnerships are structured to cover direct costs upfront, allowing for efficient capital allocation [23]. Financial Management - Recursion has reduced pro forma expenses by 35%, aiming for operational excellence [27]. - The company is focused on maintaining a disciplined approach to capital allocation, with a dynamic business model that allows for quick pivots based on pipeline results [58]. Data Strategy - Recursion emphasizes the importance of proprietary data, holding 40 petabytes of data that enhances its drug discovery capabilities [29][39]. - The company is actively seeking partnerships to enhance its data assets, recognizing that no single provider has all necessary data [64]. Talent Acquisition and Management - The company faces challenges in recruiting talent that is proficient in both AI and drug discovery [52]. - Recursion aims to create a culture that values both scientific and AI expertise, which is crucial for innovation [55]. Market Dynamics - The drug discovery market is still largely untapped, with only about 3% of the genome having an approved drug [77]. - Recursion believes that the industry’s high failure rate is due to insufficient data and predictive models [78]. Future Outlook - The company is optimistic about its ability to innovate and leverage its data for better drug discovery outcomes [80]. - Recursion is committed to building a robust pipeline and maintaining flexibility in its capital strategy to adapt to market conditions [58]. Additional Insights - The integration of AI in drug discovery is seen as a significant advantage, allowing Recursion to simulate more and produce less, leading to greater efficiency [32][39]. - The company is focused on both breadth and depth in its partnerships, ensuring high-quality data for specific patient populations [66]. This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Recursion Pharmaceuticals' commitment to innovation, efficiency, and effective partnership management in the biotech industry.

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [24] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [25] - Total cash inflow for the year amounted to $32 million, bolstered by public offerings and the exercise of investor warrants [19][20] Business Line Data and Key Metrics Changes - The EVX-01 program for advanced melanoma showed a high objective response rate of 75% and a complete response rate of 25% based on 2-year phase 2 data [10] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [12] - The EVX-B2 program targeting Neisseria gonorrhoeae retained full global rights, with strong preclinical data indicating significant protection in mouse models [14] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][6] - The autoimmune disease market is characterized by over 14 million patients annually in the U.S., presenting a significant opportunity for the company's platform [7] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [32] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [51] - The company is committed to deriving value from its platform and pipeline assets through partnerships [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [30] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [27] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [60] Other Important Information - The company received recognition from the Galien Foundation for its AI advances in human health [5] - The automated vaccine design module launched in October 2025 enhances the design cycle, reducing costs and development time [18] Q&A Session Summary Question: Changes to strategy under new CEO - The CEO noted that the fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [30] Question: Regulatory submission for EVX-04 - The CEO indicated that while initial proof of concept is important, further validation data will strengthen the value proposition for external partners [34] Question: Partnering efforts for EVX-01 - The CEO mentioned that strong clinical data and translational insights are key to driving interest from potential partners [41] Question: Autoimmune disease strategy - The company is analyzing prevalent autoimmune diseases to identify suitable indications for its platform [72]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap comparison [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, or 64% of total revenue, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16][18] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company and certain former executives were dismissed in full [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [33][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in drug discovery and efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing efficiency in customer workflows [43] Question: Revenue guidance and potential seasonality - Management expressed optimism for Q1, indicating no serious negative comps and a diverse set of customers driving orders [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94] Question: Traction in new product lines - The ModTail technology has seen strong early adoption, generating over $1 million in orders, and the company plans to launch more kits in 2026 [98]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [6][19] - Adjusted EBITDA for Q4 was positive at $536,000, marking the first return to positive adjusted EBITDA in four quarters, an improvement of approximately $11 million sequentially from Q3 [7][21] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [20] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap revenue [19][24] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [19][25] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [24][25] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [20] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [15] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, and enhance customer engagement, positioning TriLink as a key player in the mRNA and gene-based therapeutic workflow [6][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [12][14] - The company is focused on operational discipline and cost-saving measures, exceeding initial targets and positioning for revenue growth and positive cash flow in 2026 [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing improved visibility and strong order volumes, particularly in GMP consumables and larger orders in Discovery [14][34] - The broader biotech environment appears to be stabilizing, with signs of recovery in biopharma funding, although smaller players remain cautious [14][16] - Customer feedback indicates a constructive FDA stance in areas like cell and gene therapy, which is expected to support ongoing program advancements [17] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [28] - The securities class action lawsuits against the company and certain former executives were dismissed in full [29] Q&A Session Summary Question: Visibility and order volume tracking for 2026 - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating confidence in forecasts for the year [33][34] Question: Demand factors for GMP consumables - Growth in GMP consumables is attributed to a broad set of customers rather than a single program, reflecting a diverse customer base [35][36] Question: Gross margin expansion details - Gross margin expansion of 1,200 basis points is driven by $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [39] Question: Current mRNA pipeline trends - Management estimates about a third market share in the mRNA ecosystem, with growth expected as more programs transition from discovery to GMP [60][64] Question: COVID CleanCap revenue expectations - The company expects total COVID CleanCap revenue of $10 million-$20 million for 2026, all anticipated in the first half of the year [91][93]

Financial Data and Key Metrics Changes - Schrödinger reported a total revenue of $256 million for 2025, reflecting a 23% growth compared to the previous year [12] - The software business generated approximately $199.5 million in revenue, with an annual contract value (ACV) of $198.5 million, showing strong growth from commercial customers [12][16] - Drug discovery revenue reached $56.4 million, more than doubling from the prior year [12][13] - The net loss for the year was $103 million, an improvement from a net loss of $187 million in 2024 [14] Business Line Data and Key Metrics Changes - Software revenue increased by 11%, while drug discovery revenue more than doubled, indicating balanced growth across business lines [12][13] - Software gross margin was 74%, down from 80% in 2024, due to higher costs associated with contribution revenue from grants [13] - Total operating expenses decreased by approximately 9% to $310 million, reflecting cost reduction initiatives [13] Market Data and Key Metrics Changes - The company experienced a challenging backdrop of tight pharma budgets and difficult biotech capital markets, yet managed to achieve significant revenue growth [12] - The materials science business grew from $15 million to $17 million as new capabilities were introduced [19] Company Strategy and Development Direction - Schrödinger aims to achieve 10%-15% software ACV growth and transition to a primarily hosted model by 2028 [10][24] - The company is focused on expanding its platform capabilities and driving increased adoption through product innovation [10][11] - The strategic pivot initiated last year is expected to position the company for long-term success [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future, citing strong performance in 2025 and a robust cash position of over $400 million [9][27] - The company anticipates continued growth in drug discovery revenue, targeting approximately $50 million annually [27] - Management acknowledged the challenges in the biotech sector but expects a recovery over the next three years [68] Other Important Information - The company is transitioning to hosted contracts, which will result in more predictable revenue but may compress gross margins in the near term [20][22] - Schrödinger's predictive toxicology solution is expected to drive additional growth, with positive feedback from beta testing [40] Q&A Session Summary Question: Impact of transitioning to hosted contracts on profitability - Management indicated that the goal for profitability by 2028 is based on growth across the software business and disciplined operating expenses [38] Question: Value of predictive toxicology in ACV guidance - Management confirmed that growth from new products, including predictive toxicology, is included in the 10%-15% growth expectation [42] Question: Dynamics of first quarter ACV versus full year - Management explained that Q1 is typically smaller due to customer budgeting cycles, and the full year guidance reflects expected growth [46] Question: Customer engagement with hosted platform transition - Management noted that customers are increasingly preferring hosted deployments, which allow for faster deployment and enhanced support [49] Question: Changes in pharma customer conversations regarding AI - Management stated that the adoption of AI is increasing demand for their software, and they are exploring integration with agentic AI solutions [53][54] Question: Customer split evolution towards ACV growth goal - Management expects recovery in biotech and new product releases to positively impact all customer segments [85]

Core Insights - Recursion has reached a pivotal moment, transitioning from demonstrating AI's role in drug discovery to showcasing an AI-native operating system that can generate clinical proof and sustainable value [3] - The company enters 2026 with five clinical programs advancing and over $500 million in milestone payments earned to date, reflecting a robust pipeline and disciplined execution strategy [3][6] Business Highlights - Recursion's pipeline is diversified, powered by its AI-native Recursion OS, with both wholly-owned and partnered programs [4] - The company achieved its first clinical validation of the Recursion OS in Familial Adenomatous Polyposis (FAP), with 75% of evaluable patients showing reductions in total polyp burden [6][9] - Recursion has received $134 million in milestone payments from its collaboration with Sanofi, with five discovery program packages accepted to date [6][14] Financial Performance - Total revenue for Q4 2025 was $35.5 million, a significant increase from $4.5 million in Q4 2024, driven by milestone payments and collaboration agreements [15] - Research and development expenses for Q4 2025 were $95.9 million, slightly lower than $98.3 million in Q4 2024, while total R&D expenses for the year were $475.3 million compared to $314.4 million in 2024 [15][22] - The net loss for Q4 2025 was $108.1 million, an improvement from a net loss of $178.9 million in Q4 2024, with a total net loss of $644.8 million for the year [15][22] Pipeline and Milestones - Recursion's pipeline includes several promising candidates, such as REC-4881 for FAP, REC-617 for advanced solid tumors, and REC-7735 for PI3Kα H1047R mutation [7][9] - Upcoming milestones include FDA engagement for REC-4881 and additional Phase 1/2 clinical data expected in 2026 [9][12] - The company anticipates further advancements in its partnered discovery programs, with potential for additional near-term milestones as programs progress [8][14] Cash Position - As of December 31, 2025, Recursion had cash and cash equivalents of $754 million, providing a runway into early 2028 without additional financing [6][15] - The company achieved a cash operating expense of approximately $399.2 million for 2025, reflecting improved operational efficiency [12][22]

Core Viewpoint - AstraZeneca PLC (NASDAQ:AZN) is enhancing its weight management portfolio through a strategic collaboration with CSPC Pharmaceuticals to develop next-generation therapies for obesity and type 2 diabetes across eight programs [1][2]. Group 1: Collaboration Details - The agreement includes the initial progress of four programs, utilizing CSPC's AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing technology [2]. - AstraZeneca will gain exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, which features one clinical-ready asset, SYH2082, and three preclinical programs [2]. Group 2: Existing Portfolio - The collaboration complements AstraZeneca's existing weight management portfolio, which includes a range of next-generation treatments targeting obesity and related complications [3]. - Current treatments in the pipeline include elecoglipron (AZD5004), AZD9550, and AZD6234, along with several preclinical assets [3]. Group 3: Company Overview - AstraZeneca PLC is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines [4]. - The company distributes its products through local representative offices and distributors [4].

Financial Data and Key Metrics Changes - In Q4 2025, the company generated revenue of $772 million, resulting in 4% organic growth, with a full-year revenue of $2.86 billion, reflecting 3% organic growth [22][24] - Adjusted EPS for Q4 was $1.70, exceeding the high end of expectations, while full-year adjusted EPS was $5.06, representing 3% growth year-over-year [10][24] - Adjusted operating margins for Q4 were 29.7%, down 60 basis points year-over-year, and for the full year, they were 27.1%, down 120 basis points year-over-year [23][24] Business Line Data and Key Metrics Changes - The diagnostics segment saw revenue of $390 million in Q4, up 10% reported and 7% organic, while the life sciences segment generated $382 million, flat on an organic basis [26][28] - For the full year, diagnostics grew 4% organically, while life sciences grew 2% organically [26][27] - The Signals software business was flat year-over-year organically in Q4 but grew in the high teens organically for the full year [27] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, with double-digit growth in Europe [26] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [26] Company Strategy and Development Direction - The company plans to continue capital deployment through share repurchases and acquisitions, having repurchased over $800 million worth of shares in 2025 [10][11] - The acquisition of ACD/Labs is expected to contribute over $20 million in revenue in 2026, adding approximately 75 basis points to overall revenue growth [12][13] - The introduction of the AI models-as-a-service platform, Signals Xynthetica, is aimed at enhancing drug development processes [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, reiterating a 2%-3% organic growth outlook for 2026 [12][31] - The company noted potential upside from improved customer sentiment in pharma and biotech, as well as ongoing cost efficiency initiatives [20][22] - Management highlighted the importance of maintaining a disciplined approach to capital deployment while navigating a fluid market environment [11][20] Other Important Information - The company generated free cash flow of $162 million in Q4, resulting in 84% conversion of adjusted net income, with a full-year free cash flow of $515 million [25] - The net debt to adjusted EBITDA leverage ratio was 2.7x, with 100% of debt being fixed rate [25] Q&A Session Summary Question: Can you provide more color on the 2%-3% organic growth framework and potential upside? - Management acknowledged positive signs in end markets since September and identified multiple paths for potential upside in both revenue and EPS [39][40] Question: What is the outlook for life sciences versus diagnostics relative to the 2%-3% growth? - Management indicated that life sciences is expected to grow at low single digits, while diagnostics is also expected to grow at low single digits, with specific growth rates for sub-segments [55] Question: How is the company approaching M&A opportunities? - Management stated that any potential M&A must provide a strong strategic addition and that they have not yet identified compelling targets [58] Question: Can you elaborate on the performance within pharma biotech and order trends? - Management noted cautious optimism and consistency in order trends, with no budget flush observed but improved clarity in the policy environment [60][61] Question: What are the expectations for the diagnostics business going into 2026? - Management expressed that diagnostics could provide upside, particularly in newborn screening and immunodiagnostics, despite taking a more prudent approach to assumptions [63][64]

Core Insights - The healthcare sector is optimistic about 2026, with expectations of better performance compared to previous years due to settled drug pricing issues, falling interest rates, and promising scientific advancements [3] Company Updates - Novo Nordisk plans to expand its incretin market with the introduction of the Wegovy oral pill and its injectable version in 2026, despite anticipating price pressures due to a recent drug pricing deal with the Trump administration and the introduction of cheaper generics [5][6] - Bristol Myers Squibb aims to deliver up to 10 new products by the end of the decade to offset losses from upcoming exclusivity expirations of blockbuster drugs, with a diverse portfolio in late-stage development [7][8] - Pfizer is heavily invested in obesity treatments following its $10 billion acquisition of Metsera, planning to launch 10 late-stage studies of obesity products by the end of the year [11][12] Business Development Strategies - Novo Nordisk is focusing on volume growth to counteract price cuts and is actively seeking complementary assets to enhance its pipeline [6] - Bristol Myers Squibb is casting a wide net for business development, aiming to build on its core therapeutic areas and pursue innovative science for challenging diseases [10] Collaborations and Investments - Eli Lilly and Nvidia announced a joint investment of up to $1 billion over five years to create a lab in San Francisco for AI-driven drug discovery [14] - AbbVie has reached an agreement with the Trump administration to lower drug prices and invest $100 billion domestically over the next decade, while also licensing an experimental cancer therapy from RemeGen for $650 million upfront, potentially worth $5.6 billion [14]